【招银国际：维持康方生物(09926.HK)“买入”评级 目标价182.12港元】智通财经APP获悉，招银国际发布研报称，维持康方生物(09926.HK)“买入”评级，认为HARMONi试验展现了积极的OS趋势，进一步增强了该行对其一线适应症潜力的信心。维持DCF估值得出的目标价不变，为182.12港元(WACC:
8.37%，永续增长率：4.5%)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.